CoChat
Sign Up
Cited by 213Cannabis and Cannabinoid ResearchSchizophrenia research and treatmentPsychedelics and Drug Studies

The DOI matches its Crossref record; 100 of the 102 references it cites were found in a registry or an index.

Cannabis and psychiatric disorders: it is not only addiction

Leweke, F. Markus, Koethe, Dagmar·2008·Addiction Biology
DOI 10.1111/j.1369-1600.2008.00106.x
Open this paper in CoChat — free account

Abstract

Since the discovery of the endocannabinoid system, a growing body of psychiatric research has emerged focusing on the role of this system in major psychiatric disorders like schizophrenia (SCZ), bipolar disorder (BD), major depression and anxiety disorder. Continuing in the line of earlier epidemiological studies, recent replication studies indicate that frequent cannabis use doubles the risk for psychotic symptoms and SCZ. Further points of clinical research interest are alterations of endocannabinoids and their relation to symptoms as well as postmortem analyses of cannabinoid CB 1 receptor densities in SCZ. A possible neurobiological mechanism for the deleterious influence of cannabis use in SCZ has been suggested, involving the disruption of endogenous cannabinoid signaling and functioning. Even though the number of studies is still limited for affective and anxiety disorders, previous results suggest these diseases to be exciting objectives of cannabinoid‐associated research. Therefore, it became apparent that cannabis use is not only frequent in patients suffering from BD, but that it also induces manic symptoms in this group. In addition, prior antipsychotic treatment decreased the numerical density of CB 1 immunoreactive glial cells in bipolar patients. Although the data on the influence of cannabis use on the development of major depression is controversial, cannabinoid compounds could display a new class of medication, as suggested by the antidepressive effects of the fatty acid amino hydrolase inhibitor URB597 in animal models. With numerous open questions and controversial results, further research is required to specify and extend the findings in this area, which provides a promising target for novel pharmacotherapeutic interventions.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1369-1600.2008.00106.x

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 102 references

Research works printed but not linked: 4

  1. Beringer K, 1932, Zur klinik des haschischrausches, Nervenarzt, 5, 337
  2. 10.1007/s00702-007-0660-5 · DOI
  3. Leweke FM, 2007, Program No 118.3.2007
  4. Moreau de Tours J‐J, 1845, Du Hachisch et de L'aliénation Mentale, Études Psychologiques

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Leweke, F. M., & Koethe, D.
Affiliations
University of Cologne (DE)
Corresponding author
Leweke, F. Markus
ORCID
Venue
Addiction Biology
Publisher
Wiley
Published
2008-06
Volume
13
Issue
2
Pages
264-275
ISSN
  • 1355-6215 (ISSN-L)
  • 1369-1600
DOI
10.1111/j.1369-1600.2008.00106.x
OpenAlex
W2113864940
Cited by
213
References
102
Citations by year
2026: 1 · 2025: 5 · 2024: 3 · 2023: 6 · 2022: 12 · 2021: 13 · 2020: 7 · 2019: 11 · 2018: 8 · 2017: 13 · 2016: 20 · 2015: 14 · 2014: 13 · 2013: 9 · 2012: 18
FWCI
2.15
Type
journal article
Language
en
Open access
closed
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor, 27 d)
Locations
  • Addiction Biology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Keywords
cannabis use, endocannabinoid system, schizophrenia, bipolar disorder, major depressive disorder, anxiety disorders, psychotic symptoms, CB1 receptor, endocannabinoids, manic symptoms, glial cells, URB597
MeSH terms
Affect, Animals, Anxiety Disorders, Bipolar Disorder, Brain, Cannabinoids, Marijuana Abuse, Cognition Disorders, Depressive Disorder, Major, Major Depressive Disorder, Drug Interactions, Humans, Psychoses, Substance-Induced, Risk Factors, Schizophrenia, Dronabinol, Antipsychotic Agents, Signal Transduction, Mood Disorders, Receptor, Cannabinoid, CB1, Cannabinoid Receptor Modulators

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review